Vietnam · Delayed Price · Currency is VND Imexpharm Statistics
Total Valuation
Imexpharm has a market cap or net worth of VND 7.72 trillion. The enterprise value is 7.69 trillion.
| Market Cap | 7.72T |
| Enterprise Value | 7.69T |
Important Dates
The next estimated earnings date is Friday, January 16, 2026.
| Earnings Date | Jan 16, 2026 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
Imexpharm has 154.01 million shares outstanding. The number of shares has increased by 8.16% in one year.
| Current Share Class | 154.01M |
| Shares Outstanding | 154.01M |
| Shares Change (YoY) | +8.16% |
| Shares Change (QoQ) | -21.83% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.42% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 23.16 and the forward PE ratio is 23.17.
| PE Ratio | 23.16 |
| Forward PE | 23.17 |
| PS Ratio | 3.15 |
| PB Ratio | 3.51 |
| P/TBV Ratio | 3.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.27, with an EV/FCF ratio of -87.40.
| EV / Earnings | 23.09 |
| EV / Sales | 3.14 |
| EV / EBITDA | 13.27 |
| EV / EBIT | 16.11 |
| EV / FCF | -87.40 |
Financial Position
The company has a current ratio of 2.81, with a Debt / Equity ratio of 0.17.
| Current Ratio | 2.81 |
| Quick Ratio | 1.44 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.64 |
| Debt / FCF | -4.24 |
| Interest Coverage | 32.83 |
Financial Efficiency
Return on equity (ROE) is 16.66% and return on invested capital (ROIC) is 12.37%.
| Return on Equity (ROE) | 16.66% |
| Return on Assets (ROA) | 10.76% |
| Return on Invested Capital (ROIC) | 12.37% |
| Return on Capital Employed (ROCE) | 20.10% |
| Revenue Per Employee | 1.68B |
| Profits Per Employee | 228.80M |
| Employee Count | 1,452 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 1.72 |
Taxes
In the past 12 months, Imexpharm has paid 101.09 billion in taxes.
| Income Tax | 101.09B |
| Effective Tax Rate | 21.82% |
Stock Price Statistics
The stock price has increased by +10.84% in the last 52 weeks. The beta is 0.72, so Imexpharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | +10.84% |
| 50-Day Moving Average | 52,232.00 |
| 200-Day Moving Average | 49,540.50 |
| Relative Strength Index (RSI) | 45.96 |
| Average Volume (20 Days) | 42,682 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imexpharm had revenue of VND 2.45 trillion and earned 333.14 billion in profits. Earnings per share was 2,163.10.
| Revenue | 2.45T |
| Gross Profit | 1.14T |
| Operating Income | 477.50B |
| Pretax Income | 463.35B |
| Net Income | 333.14B |
| EBITDA | 579.75B |
| EBIT | 477.50B |
| Earnings Per Share (EPS) | 2,163.10 |
Balance Sheet
The company has 395.75 billion in cash and 372.95 billion in debt, giving a net cash position of 22.80 billion or 148.04 per share.
| Cash & Cash Equivalents | 395.75B |
| Total Debt | 372.95B |
| Net Cash | 22.80B |
| Net Cash Per Share | 148.04 |
| Equity (Book Value) | 2.20T |
| Book Value Per Share | 14,278.60 |
| Working Capital | 1.07T |
Cash Flow
In the last 12 months, operating cash flow was -34.77 billion and capital expenditures -53.25 billion, giving a free cash flow of -88.02 billion.
| Operating Cash Flow | -34.77B |
| Capital Expenditures | -53.25B |
| Free Cash Flow | -88.02B |
| FCF Per Share | -571.52 |
Margins
Gross margin is 46.53%, with operating and profit margins of 19.47% and 14.77%.
| Gross Margin | 46.53% |
| Operating Margin | 19.47% |
| Pretax Margin | 18.89% |
| Profit Margin | 14.77% |
| EBITDA Margin | 23.64% |
| EBIT Margin | 19.47% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 1.00%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 1.00% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 21.26% |
| Buyback Yield | -8.16% |
| Shareholder Yield | -7.13% |
| Earnings Yield | 4.32% |
| FCF Yield | -1.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Sep 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Imexpharm has an Altman Z-Score of 7.83 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.83 |
| Piotroski F-Score | 3 |